In human U87MG glioblastoma cells cultured with 10% FBS, temozolomide (TMZ) at 800 µM reduced the MTT signal by about 40% at 24–48 h and about 20% at 72 h; 400 µM did not significantly reduce this readout. In separate experiments, 400 and 800 µM TMZ increased caspase-3 activity at 48 h but not significantly at 24 h. TMZ at 800 µM produced a modest increase in PI-positive cells at 72 h, while the 48 h comparison was not significant. MTT, caspase-associated activity and PI positivity are distinct cellular readouts and do not establish a direct molecular target or clinical efficacy. The study used TMZ from Apollo Scientific and does not authenticate Adooq A10575. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Temozolomide MTT response in U87MG cells
Cell-based study · Human U87MG glioblastoma cells (ATCC HTB-14), medium containing 10% FBS [1]
At 800 µM, TMZ significantly reduced the MTT signal at 24, 48 and 72 h; the authors describe about 40% reduction at 24–48 h and about 20% at 72 h. The reduction at 72 h was smaller, not progressively greater. At 400 µM the reduction was not significant in this serum-containing model. MTT measures metabolic reduction and cannot alone distinguish cytostasis, metabolic suppression and cell death.
Literature-Reported Treatment Conditions
- Treatment concentration
- 400 and 800 µM
- Exposure duration
- 24, 48 and 72 h
- Method
- TMZ exposure in culture medium; MTT readout normalized to matched vehicle-treated cells.
- Vehicle
- TMZ dilutions in 1:1 water/DMSO; matched vehicle controls. Methods state a final solvent concentration of 1%; this is not relabeled as 1% DMSO.
- Reported limits
- Exact numerical means and SEM are not tabulated for the adopted figure panel; approximate reductions are taken from the authors’ prose, not calculated from pixels. Supplier catalog/lot and compound purity are not reported in the checked Chemicals paragraph.
Methods and source locations
Compound reported in the paper: Temozolomide; Compound label in the paper: TMZ
Published temozolomide compound-level findings; the reported material was from Apollo Scientific. No use, equivalence testing or lot certification of Adooq A10575 is established.
Sec3/Par8; Sec4/Par9; Sec5/Par12–15; Sec6/Par16; Sec14/Par25; Sec16/Par28; Fig4A and caption
Vehicle-normalized MTT signal at 800 µM TMZ: MTT reduction assay; mean ± SEM from 5 independent experiments in Figure 4; no numerical digitization. — Sec16/Par28 and Fig4A/caption
MTT response at 400 µM TMZ: MTT reduction assay; five independent experiments in Figure 4. — Sec16/Par28 and Fig4A/caption
Temozolomide-associated caspase-3 activity and PI positivity in U87MG cells
Cell-based study · Human U87MG glioblastoma cells (ATCC HTB-14) [1]
TMZ at 400 and 800 µM increased caspase-3 activity at 48 h, but not significantly at 24 h. At 800 µM, PI positivity increased modestly and significantly at 72 h; the 48 h comparison was not significant. These are cell-death-associated readouts; neither assay establishes a direct molecular target or proves that caspase-3 is required for the response.
Literature-Reported Treatment Conditions
- Treatment concentration
- Caspase-3 assay: 400 and 800 µM TMZ; PI assay: 800 µM TMZ
- Exposure duration
- Caspase-3: 24 and 48 h; PI: 48 and 72 h
- Method
- Separate culture experiments with fluorogenic caspase-3 substrate cleavage or PI flow cytometry.
- Vehicle
- TMZ dilutions in 1:1 water/DMSO; matched vehicle controls. Methods state a final solvent concentration of 1%; this is not relabeled as 1% DMSO.
- Reported limits
- Exact numerical means and SEM for the selected panels are not tabulated. Assay-associated activity/PI positivity does not itself establish causal pathway dependence.
Methods and source locations
Compound reported in the paper: Temozolomide; Compound label in the paper: TMZ
Published temozolomide compound-level findings; the reported material was from Apollo Scientific. No use, equivalence testing or lot certification of Adooq A10575 is established.
Sec3/Par8; Sec4/Par9; Sec5/Par15; Sec8/Par18; Sec9/Par19; Sec14/Par25; Sec17/Par39; Fig5A–B/caption
Caspase-3-associated substrate cleavage after TMZ exposure: Fluorogenic Ac-DEVD-AMC substrate assay, normalized to protein and then vehicle; mean ± SEM from 3–4 independent experiments, with two replicates in methods. — Sec9/Par19; Sec17/Par39; Fig5B/caption
PI-positive U87MG cells after 800 µM TMZ: PI staining and flow cytometry; mean ± SEM from 3–4 independent experiments, two replicates in methods. — Sec8/Par18; Sec17/Par39; Fig5A/caption